|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yoda S, Dagogo-Jack I and Hata AN:
Targeting oncogenic drivers in lung cancer: Recent progress,
current challenges and future opportunities. Pharmacol Ther.
193:20–30. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Remon J, Ahn MJ, Girard N, Johnson M, Kim
DW, Lopes G, Pillai RN, Solomon B, Villacampa G and Zhou Q:
Advanced stage non-small cell lung cancer: Advances in thoracic
oncology 2018. J Thorac Oncol. 14:1134–1155. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng L, Wang Y, Xu Z, Yang Q, Zhu G, Liao
XY, Chen X, Zhu B, Duan Y and Sun J: Concurrent EGFR-TKI and
thoracic radiotherapy as first-line treatment for stage IV
non-small cell lung cancer harboring EGFR active mutations.
Oncologist. 24:e1031–e1612. 2019. View Article : Google Scholar
|
|
5
|
Gao J, Li HR, Jin C, Jiang JH and Ding JY:
Strategies to overcome acquired resistance to EGFR TKI in the
treatment of non-small cell lung cancer. Clin Transl Oncol.
21:1287–1301. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee CK, Kim S, Lee JS, Lee JE, Kim SM,
Yang IS, Kim HR, Lee JH, Kim S and Cho BC: Next-generation
sequencing reveals novel resistance mechanisms and molecular
heterogeneity in EGFR-mutant non-small cell lung cancer with
acquired resistance to EGFR-TKIs. Lung Cancer. 113:106–114. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ahsan A: Mechanisms of resistance to EGFR
tyrosine kinase inhibitors and therapeutic approaches: An update.
Adv Exp Med Biol. 893:137–153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu X, Chen L, Liu L and Niu X:
EMT-mediated acquired EGFR-TKI resistance in NSCLC: Mechanisms and
strategies. Front Oncol. 9:10442019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sato H, Shien K, Tomida S, Okayasu K,
Suzawa K, Hashida S, Torigoe H, Watanabe M, Yamamoto H, Soh J, et
al: Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI
resistance non-small cell lung cancer cells harboring EMT features.
Sci Rep. 7:408472017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shah R and Lester JF: Tyrosine kinase
inhibitors for the treatment of EGFR mutation-positive
non-small-cell lung cancer: A clash of the generations. Clin Lung
Cancer. Dec 20–2019.(Epub ahead of print). PubMed/NCBI
|
|
11
|
Ma Y, Tang N, Thompson RC, Mobley BC,
Clark SW, Sarkaria JN and Wang J: InsR/IGF1R pathway mediates
resistance to EGFR inhibitors in glioblastoma. Clin Cancer Res.
22:1767–1776. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu SG and Shih JY: Management of acquired
resistance to EGFR TKI-targeted therapy in advanced non-small cell
lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Murtuza A, Bulbul A, Shen JP, Keshavarzian
P, Woodward BD, Lopez-Diaz FJ, Lippman SM and Husain H: Novel
third-generation EGFR tyrosine kinase inhibitors and strategies to
overcome therapeutic resistance in lung cancer. Cancer Res.
79:689–698. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carlisle JW and Ramalingam SS: Role of
osimertinib in the treatment of EGFR-mutation positive
non-small-cell lung cancer. Future Oncol. 15:805–816. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Frixa T, Donzelli S and Blandino G:
Oncogenic MicroRNAs: Key players in malignant transformation.
Cancers (Basel). 7:2466–2485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sin TK, Wang F, Meng F, Wong SC, Cho WC,
Siu PM, Chan LW and Yung BY: Implications of MicroRNAs in the
treatment of gefitinib-resistant non-small cell lung cancer. Int J
Mol Sci. 17:2372016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zang H, Wang W and Fan S: The role of
microRNAs in resistance to targeted treatments of non-small cell
lung cancer. Cancer Chemother Pharmacol. 79:227–231. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li B, Ren S, Li X, Wang Y, Garfield D,
Zhou S, Chen X, Su C, Chen M, Kuang P, et al: MiR-21 overexpression
is associated with acquired resistance of EGFR-TKI in non-small
cell lung cancer. Lung Cancer. 83:146–153. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu J, Tao L and Jin L: MicroRNA506-3p
reverses gefitinib resistance in non-small cell lung cancer by
targeting Yes-associated protein 1. Mol Med Rep. 19:1331–1339.
2019.PubMed/NCBI
|
|
20
|
Ma W, Feng W, Tan J, Xu A, Hu Y, Ning L,
Kang Y, Wang L and Zhao Z: miR-497 may enhance the sensitivity of
non-small cell lung cancer cells to gefitinib through targeting the
insulin-like growth factor-1 receptor. J Thorac Dis. 10:5889–5897.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koizumi F, Shimoyama T, Taguchi F, Saijo N
and Nishio K: Establishment of a human non-small cell lung cancer
cell line resistant to gefitinib. Int J Cancer. 116:36–44. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrows-wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kozomara A and Griffiths-Jones S: miRBase:
Annotating high confidence microRNAs using deep sequencing data.
Nucleic Acids Res. 42:D68–D73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Schneider VA, Graves-Lindsay T, Howe K,
Bouk N, Chen HC, Kitts PA, Murphy TD, Pruitt KD, Thibaud-Nissen F,
Albracht D, et al: Evaluation of GRCh38 and de novo haploid genome
assemblies demonstrates the enduring quality of the reference
assembly. Genome Res. 27:849–864. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim D, Langmead B and Salzberg SL: HISAT:
A fast spliced aligner with low memory requirements. Nat Methods.
12:357–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schaid DJ, Sinnwell JP and Thibodeau SN:
Robust multipoint identical-by-descent mapping for affected
relative pairs. Am J Hum Genet. 76:128–138. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D,
Liu Z and Huang J: Expression profile analysis of microRNAs and
downregulated miR-486-5p and miR-30a-5p in non-small cell lung
cancer. Oncol Rep. 34:1779–1786. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu J, Zeng Y, Li W, Qin H, Lei Z, Shen D,
Gu D, Huang JA and Liu Z: CD73/NT5E is a target of miR-30a-5p and
plays an important role in the pathogenesis of non-small cell lung
cancer. Mol Cancer. 16:342017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weng CH, Chen LY, Lin YC, Shih JY, Lin YC,
Tseng RY, Chiu AC, Yeh YH, Liu C, Lin YT, et al:
Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per
se is a common mechanism for acquired resistance to EGFR TKI.
Oncogene. 38:455–468. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Debruyne DN, Bhatnagar N, Sharma B, Luther
W, Moore NF, Cheung NK, Gray NS and George RE: ALK inhibitor
resistance in ALK(F1174L)-driven neuroblastoma is associated with
AXL activation and induction of EMT. Oncogene. 35:3681–3691. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu F, Li J, Jang C, Wang J and Xiong J:
The role of Axl in drug resistance and epithelial-to-mesenchymal
transition of non-small cell lung carcinoma. Int J Clin Exp Pathol.
7:6653–6661. 2014.PubMed/NCBI
|
|
33
|
Lin RL and Zhao LJ: Mechanistic basis and
clinical relevance of the role of transforming growth factor-β in
cancer. Cancer Biol Med. 12:385–393. 2015.PubMed/NCBI
|
|
34
|
Tan EJ, Olsson AK and Moustakas A:
Reprogramming during epithelial to mesenchymal transition under the
control of TGFβ. Cell Adhes Migr. 9:233–246. 2015. View Article : Google Scholar
|
|
35
|
Jin Q, Gao G and Mulder KM: Requirement of
a dynein light chain in TGFbeta/Smad3 signaling. J Cell Physiol.
221:707–715. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shirai K, Saika S, Tanaka T, Okada Y,
Flanders KC, Ooshima A and Ohnishi Y: A new model of anterior
subcapsular cataract: Involvement of TGFbeta/Smad signaling. Mol
Vis. 12:681–691. 2006.PubMed/NCBI
|
|
37
|
Nukaga S, Yasuda H, Tsuchihara K, Hamamoto
J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S,
et al: Amplification of EGFR wild-type alleles in non-small cell
lung cancer cells confers acquired resistance to mutation-selective
EGFR tyrosine kinase inhibitors. Cancer Res. 77:2078–2089. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Corallo S, D'Argento E, Strippoli A, Basso
M, Monterisi S, Rossi S, Cassano A and Barone CM: Treatment options
for EGFR T790M-negative EGFR tyrosine kinase inhibitor-resistant
non-small cell lung cancer. Target Oncol. 12:153–161. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee CG, McCarthy S, Gruidl M, Timme C and
Yeatman TJ: MicroRNA-147 induces a mesenchymal-to-epithelial
transition (MET) and reverses EGFR inhibitor resistance. PLoS One.
9:e845972014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu FY, Cao XN, Xu QZ, Deng Y, Lai SY, Ma J
and Hu JB: miR-124 modulates gefitinib resistance through SNAI2 and
STAT3 in non-small cell lung cancer. J Huazhong Univ Sci Technolog
Med Sci. 36:839–845. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kitamura K, Seike M, Okano T, Matsuda K,
Miyanaga A, Mizutani H, Noro R, Minegishi Y, Kubota K and Gemma A:
MiR-134/487b/655 cluster regulates TGF-β-induced
epithelial-mesenchymal transition and drug resistance to gefitinib
by targeting MAGI2 in lung adenocarcinoma cells. Mol Cancer Ther.
13:444–453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kang CW, Han YE, Kim J, Oh JH, Cho YH and
Lee EJ: 4-Hydroxybenzaldehyde accelerates acute wound healing
through activation of focal adhesion signalling in keratinocytes.
Sci Rep. 7:141922017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang J and Gu J:
Beta1,4-galactosyltransferase V A growth regulator in glioma.
Methods Enzymol. 479:3–23. 2010. View Article : Google Scholar : PubMed/NCBI
|
